Man Group
CLVS

Man Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Man Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,535
Closed -$15K – 2337
2022
Q3 		$15K Buy
+12,535
New +$19.5K ﹤0.01% 1950
2022
Q2 		– Sell
-32,732
Closed -$48.3K – 1975
2022
Q1 		$66K Sell
32,732
-24,868
-43% -$48.9K ﹤0.01% 2099
2021
Q4 		$156K Buy
+57,600
New +$213K ﹤0.01% 1837
2020
Q3 		– Sell
-49,894
Closed -$336K – 1910
2020
Q2 		$336K Buy
+49,894
New +$378K ﹤0.01% 1530
2019
Q4 		– Sell
-193,388
Closed -$760K – 1946
2019
Q3 		$760K Buy
193,388
+23,864
+14% +$193K ﹤0.01% 1498
2019
Q2 		$2.52M Buy
169,524
+2,000
+1% +$36.1K 0.01% 1227
2019
Q1 		$4.16M Sell
167,524
-159,746
-49% -$4M 0.02% 1006
2018
Q4 		$5.88M Buy
327,270
+238,697
+269% +$4.88M 0.03% 695
2018
Q3 		$2.6M Sell
88,573
-69,395
-44% -$2.69M 0.01% 1303
2018
Q2 		$7.18M Buy
+157,968
New +$7.68M 0.03% 751

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Man Group's CLVS Position: Q4 2022 in Review

Man Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 12,535 shares — an estimated $15K sold.

Man Group first reported a position in CLVS in Q2 2018 and held it in 10 quarters. The position peaked at $7.18M in Q2 2018. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Man Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Man Group sold 12,535 Clovis Oncology, Inc. shares in Q4 2022, an estimated $15K.
  • Man Group first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 10 quarters.
  • Man Group's Clovis Oncology, Inc. position peaked at $7.18M in Q2 2018.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.